gossypol has been researched along with Angiogenesis, Pathologic in 9 studies
Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thus, we hypothesized that BH3-mimetic drugs that antagonize Bcl-2 family proteins may exert a greater efficacy when dosed metronomically." | 1.38 | Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects. ( Dong, Z; Imai, A; Krishnamurthy, S; Light, E; Nör, JE; Visioli, F; Wang, S; Worden, F; Zeitlin, BD; Zhang, Z, 2012) |
| " Notably, the growth of human prostate tumor PC-3 xenografts in mice was significantly suppressed by (-)-gossypol at a dosage of 15 mg/kg/d." | 1.37 | (-)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis. ( Chen, J; Liu, M; Lu, B; Pang, X; Qu, W; Wang, J; Wu, Y; Yi, Z, 2011) |
| "Gossypol treatment affects angiogenic cytokine secretion from these two cell lines in a different manner." | 1.35 | Profiling of angiogenic cytokines produced by hormone- and drug-refractory prostate cancer cell lines, PC-3 and DU-145 before and after treatment with gossypol. ( Atmaca, H; Cengiz, E; Erten, C; Gorumlu, G; Gul, MK; Karabulut, B; Karaca, B; Kucukzeybek, Y; Sanli, UA; Uslu, R; Uzunoglu, S, 2008) |
| "The majority of human prostate cancers overexpress the important antiapoptotic proteins Bcl-2 and/or Bcl-xL, which render tumors resistant to radiation therapy." | 1.33 | (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. ( Chen, J; Davis, M; Lawrence, T; Lippman, ME; Liu, M; Rae, JM; Tang, W; Wang, S; Xu, L; Yang, D, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| El-Lakkany, NM | 1 |
| Elkattan, HH | 1 |
| Elsisi, AE | 1 |
| Ren, T | 1 |
| Shan, J | 1 |
| Li, M | 1 |
| Qing, Y | 1 |
| Qian, C | 1 |
| Wang, G | 1 |
| Li, Q | 1 |
| Lu, G | 1 |
| Li, C | 1 |
| Peng, Y | 1 |
| Luo, H | 1 |
| Zhang, S | 1 |
| Yang, Y | 1 |
| Cheng, Y | 1 |
| Wang, D | 1 |
| Zhou, SF | 1 |
| Karaca, B | 2 |
| Kucukzeybek, Y | 1 |
| Gorumlu, G | 1 |
| Erten, C | 1 |
| Gul, MK | 1 |
| Cengiz, E | 1 |
| Atmaca, H | 1 |
| Uzunoglu, S | 2 |
| Sanli, UA | 2 |
| Karabulut, B | 2 |
| Uslu, R | 2 |
| Varol, U | 1 |
| Tunali, D | 1 |
| Degirmenci, M | 1 |
| Cirak, Y | 1 |
| Purcu, DU | 1 |
| Sezgin, C | 1 |
| Zhang, XQ | 1 |
| Huang, XF | 1 |
| Mu, SJ | 1 |
| An, QX | 1 |
| Xia, AJ | 1 |
| Chen, R | 1 |
| Wu, DC | 1 |
| Pang, X | 1 |
| Wu, Y | 2 |
| Lu, B | 1 |
| Chen, J | 2 |
| Wang, J | 1 |
| Yi, Z | 1 |
| Qu, W | 1 |
| Liu, M | 2 |
| Imai, A | 1 |
| Zeitlin, BD | 1 |
| Visioli, F | 1 |
| Dong, Z | 1 |
| Zhang, Z | 1 |
| Krishnamurthy, S | 1 |
| Light, E | 1 |
| Worden, F | 1 |
| Wang, S | 2 |
| Nör, JE | 1 |
| Jiang, J | 1 |
| Slivova, V | 1 |
| Jedinak, A | 1 |
| Sliva, D | 1 |
| Xu, L | 1 |
| Yang, D | 1 |
| Tang, W | 1 |
| Davis, M | 1 |
| Rae, JM | 1 |
| Lawrence, T | 1 |
| Lippman, ME | 1 |
9 other studies available for gossypol and Angiogenesis, Pathologic
| Article | Year |
|---|---|
The ponatinib/gossypol novel combination provides enhanced anticancer activity against murine solid Ehrlich carcinoma via triggering apoptosis and inhibiting proliferation/angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptos | 2021 |
Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; | 2015 |
Profiling of angiogenic cytokines produced by hormone- and drug-refractory prostate cancer cell lines, PC-3 and DU-145 before and after treatment with gossypol.
Topics: Antineoplastic Agents; Caspase 3; Caspase 7; Cell Line, Tumor; Cytokines; Drug Resistance, Neoplasm; | 2008 |
The effect of racemic gossypol and at-101 on angiogenic profile of ovcar-3 cells: a preliminary molecular framework for gossypol enantiomers.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; DNA Frag | 2009 |
Inhibition of proliferation of prostate cancer cell line, PC-3, in vitro and in vivo using (-)-gossypol.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell | 2010 |
(-)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis.
Topics: Animals; Aorta; Apoptosis; bcl-X Protein; Cell Differentiation; Cell Line; Cell Movement; Cell Proli | 2011 |
Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2012 |
Gossypol inhibits growth, invasiveness, and angiogenesis in human prostate cancer cells by modulating NF-κB/AP-1 dependent- and independent-signaling.
Topics: Cell Division; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; G1 Phase; Gossypol; Humans; I | 2012 |
(-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer.
Topics: Animals; Apoptosis; bcl-X Protein; Combined Modality Therapy; Gossypol; Humans; Male; Neovasculariza | 2005 |